Sterling Capital Management LLC Has $2.44 Million Position in Kenvue Inc. (NYSE:KVUE)

Sterling Capital Management LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 55.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 114,247 shares of the company’s stock after purchasing an additional 40,694 shares during the period. Sterling Capital Management LLC’s holdings in Kenvue were worth $2,439,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Grove Bank & Trust increased its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter worth $29,000. SRS Capital Advisors Inc. increased its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC raised its stake in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc boosted its holdings in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research analyst reports. Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Barclays lifted their price target on shares of Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 27th. Finally, Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.42.

Kenvue Stock Performance

NYSE KVUE opened at $22.10 on Monday. The firm has a market cap of $42.25 billion, a price-to-earnings ratio of 41.71, a PEG ratio of 2.62 and a beta of 1.02. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a 50 day moving average of $22.65 and a 200-day moving average of $22.40.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.71%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.